BioCentury
ARTICLE | Company News

Angiogene Pharmaceuticals, OxiGene deal

July 2, 2012 7:00 AM UTC

Angiogene granted OxiGene exclusive, worldwide rights to IP, patents and preclinical data related to Angiogene's vascular disrupting agent to treat carcinoid syndrome. OxiGene plans to use the IP to develop its Zybrestat fosbretabulin to treat carcinoid syndrome associated with metastatic carcinoid and neuroendocrine tumors. The company plans to begin a Phase II trial of the A4 prodrug phosphatase-activated tumor vascular targeting agent in the indication by year end. Angiogene will receive an upfront payment and is eligible for milestones and royalties. Details were not disclosed. ...